Eginitio Hospital — Clinical Trial Site

36 Registered trials

14 Currently recruiting

Organisation

Eginitio Hospital

Location

Athens, Greece

Identifier

ORG-100047732

Address

Vassilissas Sofias Avenue 74, 115 28, Greece

Departments

#1401: Department of Neurology
1 st University Neurology Clinic
1st Department of Neurology
1st Department of Neurology
1st Department of Neurology, NKUA
1st Department of Psychiatry
1st Department of Psychiatry of the National and Kapodistrian University of Athens
1st Neurology Department
1st Neurology Department of National and Kapodistrian University of Athens
1st Neurology Department of NKUA
1st University Neurology Clinic
2403:Neurology Clinic
40850: A' Department of Neurology
A' Neurological Clinic
A’ Department of Neurology
A’ Neurology Clinic
A’ Neurology Department
A’ Neurology Department of University of Athens
A’ Psychiatric Clinic
First Department of Psychiatry
Neurology department

Clinical trials at this site (36)

Search interface

Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND) Pending

2024-516805-22-00 Major Depressive Disorder 5
Open-label Extension of KarXT + KarX-EC for Agitation in Alzheimer’s Disease Pending

2024-519994-20-00 Agitation Associated with Alzheimer’s Disease 5
A study to test if tenecteplase helps people to recover from an acute stroke when given more than 4.5 hours after the person was last seen w… Pending

2025-522542-40-00 Acute Ischemic Stroke 5
A Phase 3 Study of Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis Pending

2025-524316-11-00 Primary Progressive Multiple Sclerosis (PPMS) 5
MP: ADAPT Forward - Master protocol of a platform study to evaluate the safety and efficacy of multiple regimens in participants with Myasth… Recruiting

2025-522492-28-00 AChR-Ab Seropositive Generalized Myasthenia Gravis, Mya 4 2026-03-13
A study to assess the efficacy and safety of empasiprubart in adults with CIDP Recruiting

2025-520805-10-00 Chronic inflammatory demyelinating polyneuropathy (CIDP 5 2026-03-12
A Phase 3 Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer’s Disease Recruiting

2025-520746-30-00 Mild to moderate Alzheimer’s Disease 5 2025-11-18
A randomised, controlled trial to investigate the effect of a six-week intensified pharmacological treatment for bipolar depression compared… Recruiting

2023-506605-19-00 Bipolar depression 5 2025-02-11
A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosi… Recruiting

2025-521546-23-00 Secondary progressive multiple sclerosis 5 2026-04-21
A Phase 2b Study of IMVT-1402 Treatment in CIDP Recruiting

2024-517614-14-00 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP 4 2025-11-28
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis Recruiting

2024-515979-35-00 Generalized Myasthenia Gravis 5 2025-11-13
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated with Alzheimer’s Disease. Recruiting

2025-520613-31-00 Agitation Associated with Alzheimer’s Disease 5 2025-10-31
A Phase 3 Trial to Assess CYB003 in Major Depressive Disorder Recruiting

2024-519270-40-00 Major Depressive Disorder 5 2025-10-30
A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy, safety, and tolerability of iptacopan in patients w… Recruiting

2023-507064-39-00 generalized Myasthenia Gravis 5 2024-09-26
A randomised, controlled trial to investigate the effect of a six-week intensified pharmacological treatment for major depressive disorder c… Recruiting

2023-506617-21-00 Major depressive disorder 5 2024-08-29
A study to investigate long-term safety and tolerability of tolebrutinib in participants with multiple sclerosis Recruiting

2023-503631-18-01 Nervous system diseases 5 2024-05-20
A study to assess the long-term safety and efficacy of a subcutaneous formulation of efgartigimod in adults with active idiopathic inflammat… Recruiting

2022-502851-79-00 Active Idiopathic Inflammatory Myopathy (IIM) 5 2023-09-20
A study to assess efficacy and safety of efgartigimod PH20 SC in adults with ocular myasthenia gravis Ended

2024-514133-38-00 Ocular Myasthenia Gravis 5 2025-03-19
A Phase 3 study to evaluate the Efficacy and Safety of Efgartigimod IV in Patients with Acetylcholine Receptor Binding Antibody Seronegative… Ended

2024-511796-15-00 Acetylcholine Receptor Binding Antibody Seronegative Ge 5 2024-10-16
A study to investigate the efficacy and safety of efgartigimod PH20 SC in adult participants with active idiopathic inflammatory myopathy Ended

2024-512785-33-00 Active Idiopathic Inflammatory Myopathy (IIM) 10 2023-03-01
A study to learn if Rozanolixizumab works and is safe over a long period in adults with relapsing myelin oligodendrocyte glycoprotein antibo… Ended

2023-509237-39-00 Myelin oligodendrocyte glycoprotein antibody-associated 5 2022-08-02
A study to evaluate the effect of venglustat tablets on neuropathic and abdominal pain in male and female participants ≥16 years of age with… Ended

2024-511990-31-00 Fabry Disease 5 2022-06-28
Efficacy and safety of remibrutinib compared to teriflunomide in participants with relapsing multiple sclerosis, followed by long term treat… Ended

2023-509372-41-00 Multiple Sclerosis 5 2022-01-30
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared with Ocrelizumab in Adult Patients with Primary Progressive Multiple Sc… Ended

2022-502611-10-00 Primary Progressive Multiple Sclerosis (PPMS) 5 2020-11-24